XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Brokerages

XOMA Royalty Corporation (NASDAQ:XOMA) has been assigned a consensus rating of “Hold” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $53.75.

XOMA has been the topic of several analyst reports. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 29th. Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Benchmark cut XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Finally, TD Cowen upgraded XOMA Royalty to a “hold” rating in a report on Friday, February 13th.

Hedge Funds Weigh In On XOMA Royalty

A number of institutional investors and hedge funds have recently modified their holdings of the business. Woodline Partners LP raised its position in shares of XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock worth $3,359,000 after purchasing an additional 12,284 shares during the period. Geode Capital Management LLC raised its position in shares of XOMA Royalty by 9.1% during the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock worth $5,132,000 after purchasing an additional 16,929 shares during the period. JPMorgan Chase & Co. raised its position in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the period. Rhumbline Advisers raised its position in shares of XOMA Royalty by 18.0% during the second quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock worth $334,000 after purchasing an additional 2,019 shares during the period. Finally, Marshall Wace LLP raised its position in shares of XOMA Royalty by 12.2% during the second quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 1,775 shares during the period. 95.92% of the stock is currently owned by institutional investors.

XOMA Royalty Stock Up 0.0%

Shares of NASDAQ XOMA opened at $41.70 on Thursday. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.96. The company has a market cap of $522.92 million, a price-to-earnings ratio of 26.56 and a beta of 0.88. XOMA Royalty has a 12 month low of $22.29 and a 12 month high of $42.81. The stock has a 50-day moving average price of $38.64 and a two-hundred day moving average price of $31.33.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The firm had revenue of $12.32 million during the quarter, compared to analyst estimates of $13.91 million. As a group, analysts forecast that XOMA Royalty will post 0.9 earnings per share for the current fiscal year.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.